Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  OTC Bulletin Board - Other OTC  >  CytoDyn Inc.    CYDY

CYTODYN INC.

(CYDY)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news
The feature you requested does not exist. However, we suggest the following feature:

CytoDyn to Hold Conference Call on August 12 to Discuss Impressive Results from its Phase 2 COVID-19 Trial

share with twitter share with LinkedIn share with facebook
08/11/2020 | 03:41pm EDT

VANCOUVER, Washington, Aug. 11, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development, and Jacob Lalezari, M.D., Senior Science Advisor, will host an investment community conference call on Wednesday, August 12, 2020, to provide a comprehensive overview of the compelling results from the Company’s recently completed Phase 2 CD10 trial for COVID-19 patients with mild-to-moderate symptoms, along with an update on its Phase 3 trial for COVID-19 patients with severe-to-critical indications and the regulatory path going forward.

Management will dedicate approximately 45 minutes to address questions from analysts and investors.

Date: Wednesday, August 12, 2020
Time: 1:00 pm PT / 4:00 pm ET
Dial-In: 877-407-8291 U.S. / 201-689-8345 International

A live audio webcast may also be accessed via CytoDyn’s corporate website at www.cytodyn.com under the Investors section/IR Calendar and will be archived for 30 days. Web participants are encouraged to go to the website 15 minutes prior to the start of the call to register, download and install any necessary software. The webcast can also be accessed via the following link:

https://78449.themediaframe.com/dataconf/productusers/cydy/mediaframe/40223/indexl.html

A replay of the conference call will be available until September 12, 2020. To access the replay, interested parties may dial 877-660-6853 (U.S.) / 201-612-7415 (International) and enter conference identification number 13708404.

CONTACTS
Investors:
Cristina De Leon
Office: 360.980.8524, ext. 106
Mobile: 503.214.0872
cdeleon@cytodyn.com

Primary Logo


© GlobeNewswire 2020
share with twitter share with LinkedIn share with facebook
Latest news on CYTODYN INC.
08/11CytoDyn to Hold Conference Call on August 12 to Discuss Impressive Results fr..
GL
08/11CytoDyn Announces Clinically Significant Top-line Results from its Phase 2 Tr..
GL
08/10CYTODYN : Seeks UK Approval of Leronlimab for HIV and COVID-19
AQ
08/07CytoDyn Seeks UK Approval of Leronlimab for HIV and COVID-19
GL
08/04CytoDyn Receives Positive DSMC Recommendation for Leronlimab Phase 3 COVID-19..
GL
07/31CYTODYN INC. : Entry into a Material Definitive Agreement, Creation of a Direct ..
AQ
07/29CYTODYN : Completes Non-dilutive $28.5 Million Convertible Note Financing with C..
AQ
07/27CytoDyn to Hold Conference Call on July 30 to Provide Updates on its Two COVI..
GL
07/24CYTODYN INC. : Entry into a Material Definitive Agreement, Amendments to Article..
AQ
07/22CYTODYN : Impressive Results from CytoDyn's Phase 2 COVID-19 Trial
AQ
More news
Financials (USD)
Sales 2020 - - -
Net income 2020 -94,8 M - -
Net Debt 2020 - - -
P/E ratio 2020 -18,9x
Yield 2020 -
Capitalization 2 354 M 2 354 M -
Capi. / Sales 2020 -
Capi. / Sales 2021 6,63x
Nbr of Employees -
Free-Float 90,4%
Chart CYTODYN INC.
Duration : Period :
CytoDyn Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CYTODYN INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Average target price
Last Close Price 4,16 
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers
NameTitle
Nader Z. Pourhassan President, Chief Executive Officer & Director
Scott A. Kelly Chairman & Chief Medical Officer
Michael D. Mulholland Chief Financial Officer & SVP-Finance
Nitya G. Ray Chief Technology Officer & Head-Process Sciences
Jordan G. Naydenov Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CYTODYN INC.316.00%2 354
GILEAD SCIENCES, INC.4.80%85 379
VERTEX PHARMACEUTICALS19.60%68 206
REGENERON PHARMACEUTICALS59.49%63 018
WUXI APPTEC CO., LTD.72.11%38 435
GENMAB A/S56.53%23 954